Every tobacco-control question is asking one thing: which lever reduces population smoking most? Two interventions carry most of the points: government restrictions on smoking in public places and tobacco taxation. Individual counseling and retail rules matter, but they are not the answer the board wants when it asks about population-level impact. Start with the case that catches the most students.
Medically reviewed by Fatima Ali, DO & Kaitlyn Cocuzzo, MD✦elite
Before you scroll
A 44-year-old nonsmoker is concerned about the high rate of smoking in his community. He asks his family physician which policy he should advocate for with the local city council to most effectively reduce population-level smoking prevalence. Which of the following should the physician recommend?
Why does public-places restriction come first?
Clean-indoor-air laws (banning smoking in workplaces, restaurants, and public venues) reduce exposure for everyone, denormalize smoking as a social activity, and directly cut consumption. The evidence base from WHO FCTC countries is robust: prevalence drops within 1 to 2 years.
Why not packaging warnings?
Graphic warnings have modest effect. They raise awareness but do not meaningfully restrict behavior. The boards want the lever that changes the ENVIRONMENT, not just the label.
Why not retail density or e-cigarettes?
Retail-outlet restrictions are a weaker lever and their evidence is less consistent. E-cigarette substitution introduces new risks and is not a policy answer for population-level smoking control. The trap is picking anything that sounds specific when a broad, structural change is offered.
Scroll ↓ the evidence hierarchy comes next
Section 1 · The Levers That Move Populations
Population Tobacco Control Hierarchy
Tap each level to see what it controls, how strong the evidence is, and why the boards pick it over the alternatives.
Level 1 · Highest Evidence
Clean-Indoor-Air Laws
What they do: ban smoking in enclosed public places and workplaces. This removes passive exposure for everyone, denormalizes smoking as a social behavior, and directly reduces daily opportunity to smoke.
Evidence: consistently shown to reduce smoking prevalence within 1 to 2 years of implementation. Also reduces hospital admissions for myocardial infarction and respiratory illness.
Board key: when a vignette asks the BEST community-level policy recommendation, clean-indoor-air restrictions are the answer.
Level 1 · Highest Evidence
Tobacco Taxation
What it does: raises the price of tobacco products. Price is the single most powerful deterrent to initiation and the most effective lever for reducing youth smoking.
Evidence: a 10% price increase reduces adult consumption by roughly 4% and youth consumption by 6 to 8%. Youth have less income and higher price elasticity, so taxation hits initiation hardest.
Board key: taxation is the go-to answer for questions about reducing youth smoking prevalence at the population level.
Level 2 · Moderate Evidence
Warning Labels and Packaging Rules
What they do: graphic health warnings and plain packaging rules reduce the appeal of tobacco products and raise awareness of health risks.
Evidence: modest effect on quit intentions and some reduction in youth appeal, but smaller than taxation or clean-air laws. Do not directly restrict access or consumption.
Board key: labeling is the distractor. It is weaker than the structural interventions above. Never pick it over clean-air laws or taxation.
Level 3 · Weaker Evidence
Retail Outlet Restrictions
What they do: limit where tobacco can be sold (e.g., not near schools, pharmacies cannot sell) to reduce access and normalize purchasing.
Evidence: association studies suggest some reduction in youth access, but evidence is less consistent than taxation. Does not directly change existing smoker behavior.
Board key: retail rules are a secondary intervention. They are tested as a distractor when the question wants clean-air laws or taxation.
The Classic Trap
A question asks what a physician should recommend to a local government to reduce community smoking. Students read the choices, see "graphic package warnings" and think that sounds specific and evidence-based. The correct answer is "restrictions on smoking in public places" because it acts on the environment, not just on information. Information changes awareness; the environment changes behavior at scale.
CTLR Clean-air · Taxation · Labeling · Retail. Ranked highest to weakest. Board wants the top two.
Section 2 · The Individual Level
The 5 A's: Counseling a Smoker
Five steps the physician follows at every clinical encounter with a tobacco user. Tap each card to see the step in detail and the board-relevant nuance.
A
Ask
Screen every patient for tobacco use at every visit. This is the mandatory first step. A physician who advises before asking has skipped the gate. Board clue: "first step in the 5 A's" = Ask, always.
A
Advise
Give clear, strong, personalized advice to quit. Not a pamphlet. Not a vague mention. A direct statement: "Quitting is the single most important thing you can do for your health." Brief and unambiguous.
A
Assess
Determine the patient's willingness to quit now. If not ready: use motivational interviewing to explore barriers. If ready: move immediately to Assist. If already quit: Arrange follow-up for relapse prevention.
A
Assist
Set a quit date. Offer pharmacotherapy (NRT, varenicline, or bupropion). Provide practical counseling (anticipate withdrawal, identify triggers, build support). This is where the clinical work happens.
A
Arrange
Schedule follow-up within the first week of the quit attempt. Relapse risk is highest in the first 7 to 14 days. A call or appointment within that window significantly improves success rates.
From the Attending
Ask comes first. Every time.
A physician who advises without asking has assumed the patient still smokes. A patient who quit last month just got lectured. And a patient who cut down got no acknowledgment. Ask first, advise specifically, arrange follow-up that week. The 5 A's are sequential on purpose.
Pregnancy: preferred pharmacotherapy in pregnancy when behavioral counseling alone fails, because continued smoking is more harmful than NRT. Note: NRT is still category C but is the first-line pharmacotherapy option in pregnancy.
Partial Nicotinic Receptor Agonist
Varenicline (Chantix)
Mechanism: partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor. Reduces cravings and blunts the reward from smoking simultaneously.
Quit rates: highest of all single-agent pharmacotherapies. Approximately 3 times the unaided quit rate at 1 year.
Dosing: titrate for 1 week before the quit date (0.5 mg once daily x 3 days, then 0.5 mg twice daily x 4 days, then 1 mg twice daily). Continue for 12 weeks; extend if needed.
Key caution: not recommended in pregnancy (limited safety data). Renal dose adjustment required. The neuropsychiatric warning (depression, suicidality) was removed from the black box in 2016 after EAGLES trial showed no increased risk.
Mechanism: inhibits neuronal reuptake of dopamine and norepinephrine. Reduces nicotine withdrawal symptoms and cravings by a nicotine-independent pathway.
Quit rates: roughly doubles unaided quit rate, similar to NRT monotherapy. Less effective than varenicline as a single agent.
Board trap: patients with a prior seizure disorder cannot use bupropion. Choose NRT or varenicline instead.
Pregnancy Board Trap
A pregnant patient fails behavioral counseling alone. The board wants NRT, not varenicline (limited pregnancy safety data) and not bupropion (not preferred). NRT is the first-line pharmacotherapy in pregnancy when counseling alone is insufficient.
Varenicline wins alone Highest quit rate single agent = varenicline. Pregnancy = NRT. Seizure hx = no bupropion.
Section 4 · The Innocent Bystander
Secondhand Smoke Harms
Tap each card to see the specific harm, the population most affected, and the board-relevant connection.
Cardiovascular
Even brief exposure matters.
Secondhand smoke increases the risk of coronary artery disease and stroke in nonsmoking adults by 25 to 30%. Even 30 minutes of exposure impairs coronary blood flow. Clean-indoor-air laws reduce MI hospitalizations within months of implementation.
Lung Cancer
No safe level of exposure.
Secondhand smoke causes lung cancer in nonsmokers. Nonsmoking spouses of heavy smokers have a 20 to 30% higher lung cancer risk than nonsmoking spouses of nonsmokers. There is no established safe exposure threshold.
Childhood Respiratory
The most common board presentation.
Children exposed to household smoke have higher rates of asthma, recurrent otitis media, lower respiratory infections, and sudden infant death syndrome (SIDS). Board vignette: recurrent otitis media in a child with both parents who smoke = secondhand smoke, primary intervention is eliminating exposure.
SIDS
Maternal smoking doubles the risk.
Maternal smoking during pregnancy and postnatal secondhand smoke exposure each independently double the risk of sudden infant death syndrome. The mechanism involves altered arousal response and nicotine effects on respiratory control centers.
Maternal smoking in the first trimester is associated with increased risk of oral cleft defects. This is a teratogenic effect of tobacco components during organogenesis.
Otitis media + both parents smoke The boards love this stem. Recurrent otitis media in a child = ask about household smoking. Intervention = eliminate smoke exposure first.Clean-air law → MI drop When a state bans indoor smoking, hospital admissions for MI fall within months. This is the most-cited natural experiment in tobacco epidemiology.
Section 5 · Nuance Matters
Special Populations
Tap each question to see the answer and the reasoning. These are the cases that turn a "probably" into a precise answer.
A 24-year-old woman at 16 weeks gestation smokes 1 ppd and has failed 2 behavioral-only attempts. Is varenicline the right choice?
Incorrect. Varenicline has the highest quit rates but has limited safety data in pregnancy. It is not first-line during pregnancy. The risk-benefit calculation favors NRT when pharmacotherapy is needed after failed behavioral counseling.
Correct. NRT (patch, gum, or lozenge) is the first-line pharmacotherapy in pregnancy after failed behavioral attempts. Continued smoking is more dangerous than NRT. Bupropion is not preferred and varenicline lacks adequate pregnancy safety data.
A 16-year-old with a seizure disorder smokes and wants to quit. His family asks about medications. Which is contraindicated?
Correct. Bupropion lowers the seizure threshold and is contraindicated in patients with a current seizure disorder, eating disorders, or those undergoing abrupt alcohol or benzodiazepine withdrawal. Use NRT or varenicline (renally adjusted) instead.
Incorrect. Varenicline is safe in seizure disorder. The agent to avoid here is bupropion, which lowers the seizure threshold. Varenicline is the preferred agent for this patient.
A community program wants to reduce teen smoking initiation with a single intervention. Which is most effective?
Correct. Tobacco taxation has the highest and most consistent evidence for reducing youth smoking initiation. Youth have limited income and high price elasticity; a 10% price increase reduces youth consumption by 6 to 8%. Education programs alone show inconsistent results.
Incorrect. School-based education programs have weaker and less consistent evidence. They raise awareness but do not directly reduce access or make purchasing painful. Taxation wins for youth prevention.
Pregnancy: NRT first Failed counseling + pregnant = NRT. Not varenicline (safety data), not bupropion (not preferred). NRT with monitoring.Youth: Tax wins The most effective population intervention for teen initiation is price (taxation). Education = weaker evidence.
Section 6 · Why It Matters Clinically
Tobacco-Attributable Diseases
Tap each card to see the specific disease, the attributable fraction, and the most-tested board angle.
Lung Cancer
85% attributable to tobacco.
Smoking causes approximately 85% of lung cancer cases. The most common type in current smokers is squamous cell carcinoma (central, hilar); in former smokers and never-smokers the risk shifts toward adenocarcinoma. Annual low-dose CT screening is recommended for high-risk individuals aged 50 to 80 with 20 pack-year history who currently smoke or quit within the past 15 years.
COPD
The top preventable cause.
Tobacco is the leading cause of COPD. Cessation is the single intervention proven to slow FEV1 decline and reduce exacerbation frequency. Board question: an intervention that improves long-term COPD prognosis = smoking cessation, consistently above bronchodilators.
Cardiovascular Disease
Doubles the risk of MI.
Smoking approximately doubles the risk of myocardial infarction and stroke. Cessation reduces that excess risk by 50% within 1 year and to near-baseline within 10 years. The mechanism involves platelet activation, endothelial dysfunction, and accelerated atherosclerosis.
Bladder and Kidney Cancer
Often missed by students.
Tobacco is the leading risk factor for transitional cell carcinoma of the bladder. Carcinogens are excreted in urine, bathing the urothelium. Classic board presentation: painless hematuria in a current or former smoker = work up for bladder cancer.
Head and Neck Cancers
Synergistic with alcohol.
Squamous cell carcinoma of the oral cavity, oropharynx, larynx, and esophagus is strongly linked to tobacco, with a synergistic (multiplicative, not additive) risk from concurrent heavy alcohol use. Board trap: heavy drinker plus heavy smoker's oropharyngeal cancer risk is not just added, it is multiplied.
Buerger Disease
Tobacco is the only modifiable risk factor.
Thromboangiitis obliterans (Buerger disease) affects small and medium arteries, predominantly in young male smokers. The only effective treatment is complete cessation. Board key: young man with digital ischemia and heavy smoking history = Buerger disease, treatment = absolute cessation.
COPD: cessation over bronchodilators The intervention that best improves long-term COPD prognosis = cessation. Bronchodilators manage symptoms; cessation slows decline.Buerger = quit completely Young smoker + digital ischemia + Buerger diagnosis = the only treatment is complete smoking cessation.
Section 7 · What the Boards Actually Test
Policy Tools: Rank Them
Tap each card to confirm where it lands in the hierarchy and why boards rank it there.
Restrictions on Smoking in Public Places
Tier 1. The board answer for community policy.
WHO FCTC Article 8. Reduces exposure, denormalizes the behavior, and decreases consumption in current smokers. When a vignette asks what a physician should recommend to a city council to reduce population smoking, this is the answer.
Tobacco Taxation
Tier 1. The answer for youth initiation.
Price is the strongest deterrent to youth initiation. A 10% tax increase cuts youth consumption by 6 to 8%. The board often asks which intervention MOST reduces youth smoking: taxation wins every time.
Individual Counseling (5 A's)
Tier 2. The clinical encounter tool.
Highly effective at the individual level but does not move population prevalence the way structural policies do. On boards, 5 A's questions focus on sequence (Ask first), not on whether counseling beats taxation.
Pharmacotherapy
Tier 2. Multiplies individual success.
Doubles or triples quit rates at the individual level. Does not affect population prevalence unless widely adopted. Board questions test agent selection (varenicline = highest single-agent quit rate; NRT in pregnancy; no bupropion with seizures).
Warning Labels
Tier 3. Awareness, not behavior change.
Graphic health warnings raise awareness and reduce product appeal but do not directly restrict access or consumption. Never pick this over clean-air laws or taxation on a community-level policy question.
Retail Outlet Restrictions
Tier 3. Secondary and inconsistent.
Limiting sales points near schools may marginally reduce youth access, but the evidence is weaker than pricing or environmental restrictions. This is a common distractor. Do not confuse familiarity with effectiveness.
Community → Public Places Board asks "best community policy" = restrictions on smoking in public places. Not labeling, not retail. Structural change over information.Youth → Taxation Board asks "most reduces youth smoking" = taxation. Price elasticity is highest in teens. Wins over education every time.
Test Yourself
Six Quick Calls, Three Per Round
Three tobacco-control cases pulled from a bigger pool, reshuffled every visit. Know the lever, know why the board picks it over the alternatives. Cross out (right-click / long-press) and highlight (select text) as you read.
Clean-indoor-air laws reduce smoking prevalence within 1 to 2 years of implementation.NRT doubles unaided quit rates and is the preferred pharmacotherapy in pregnancy.Warning labels raise awareness but are weaker than structural policy interventions.Secondhand smoke is the most common preventable cause of recurrent otitis media in children.
Board Practice
Walk the Cases
Six full vignettes, one at a time, in a shuffled order. Pick your answer, then walk every option one beat at a time. The deciding clues in the stem glow once you commit. Cross out (right-click / long-press) and highlight (select text) as you go.
From the Attending
These vignettes are written the way the real exam writes them: the board will name a policy, a drug, or a patient, then ask which is most effective or which comes first. Cover the choices. Find the level: community policy, individual counseling, or pharmacotherapy. Then rank the options by evidence. Most tobacco-control traps are picking a specific intervention when a structural one is sitting right there.
Tip: kill the wrong choices first, then read the explanation chain for every option.
World Health Organization. WHO Framework Convention on Tobacco Control (FCTC). Geneva: WHO, 2003. The evidence base for population-level tobacco control including clean-indoor-air laws and taxation.
U.S. Surgeon General. The Health Consequences of Smoking: 50 Years of Progress. Atlanta: CDC, 2014. Attributable fractions for tobacco-related disease.
Fiore MC et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville: USDHHS. The source of the 5 A's framework and pharmacotherapy evidence.
Gonzales D et al. Varenicline versus sustained-release bupropion and placebo for smoking cessation. JAMA. 2006;296:47-55. Varenicline efficacy data.
American College of Obstetricians and Gynecologists. Smoking Cessation During Pregnancy. ACOG Committee Opinion 807, 2020. NRT in pregnancy guidance.
Reviewed by Fatima Ali DO and Kaitlyn Cocuzzo MD. Vignettes are original clinical teaching cases. Demographics, values, and answer order are written for practice. Pharmacotherapy dosing should be verified against current prescribing information before clinical use.
Bone Wizardry is an independent educational resource for visual learning in the medical sciences. It is not affiliated with, endorsed by, or sponsored by any licensing or examination board, contains no real or recalled examination questions, and does not guarantee any educational or examination outcome.
Free preview complete
This is where Elite starts
The hook is free. The full board walkthroughs, elimination drills, and deeper mechanics are inside Elite.
Unlock every gated Bone Wizardry page
Keep the one-at-a-time walkthrough banks
Use the diagnostic games and answer logic without limits
